News

Press Release

NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

2022-04-28

Poster discussion will highlight anti-tumor activities of NT-I7 combined with pembrolizumab in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective

 

NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022. These include one poster discussion and two poster displays.

 

Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: “We are pleased that the ASCO Scientific Program Committee selected our abstract on the efficacy and safety of NT-I7 in combination with pembrolizumab for a poster discussion. While the abstract was based on data cutoff as of January 14, 2022, the actual Phase 2a data presented and discussed at the congress will have a few additional months of follow-up. They will shed new light on the benefit of combining NT-I7 with a checkpoint inhibitor (CPI) in patients with immune-cold microsatellite stable colorectal cancer or pancreatic cancer and in those who progressed on previous CPI treatment. We are also excited to report progress made with NT-I7 administration after CAR-T infusion, another important area of potential NT-I7 use.”

 

NIT presentations at 2022 ASCO Annual Meeting:

  Primary Author

Abstract Title

  Presentation details

Naing, A

Efficacy and Safety of NT-I7, Long-Acting Interleukin-7, plus Pembrolizumab in patients with advanced solid tumors: results from the Phase 2a study

  • Abstract #2514
  • Poster discussion Session: Developmental Therapeutics

-Immunotherapy

  • June, 5 2022

11:30 AM-1:00 PM;

8:00 AM-11:00 AM CDT

Gastman, B

A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

  • Abstract #9561
  • Poster display Session: Melanoma/Skin Cancers
  • June 6, 2022

1:15 PM-4:15 PM CDT

Ghobadi, A

Trial in Progress: A phase 1b study evaluating the safety, tolerability and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma

  • Abstract # TPS7596
  • Poster display – Trial in progress (TiP) Poster Session: Hematologic Malignancies

- Lymphoma and Chronic Lymphocytic Leukemia

  • June 4, 2022

8:00 AM- 11:00 AM CDT

 

Media inquiries : press@neoimmunetech.com

 

List